Influence of Oral Doxycycline on Wound Healing After Endonasal Endoscopic Sinus Surgery for Chronic Rhinosinusitis With and Without Nasal Polyposis: a Double-blind Randomized Placebo-controlled Trial (DOXYPOSTOP)

June 14, 2018 updated by: University Hospital, Ghent

Influence of Oral Doxycycline on Wound Healing After Endonasal Endoscopic Sinus Surgery for Chronic Rhinosinusitis With and Without Nasal Polyposis: a Double-blind Randomized Placebo-controlled Trial.

This is a randomized, double blind, placebo controlled, parallel group, study in patients with chronic rhinosinusitis with or without nasal polyps. The objective is to test the clinical efficacy of long-term low dose oral doxycycline on wound healing quality after endoscopic sinus surgery.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Actual)

33

Phase

  • Phase 2

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Ghent, Belgium
        • University Hospital Ghent
      • Bochum, Germany
        • Univ.-HNO-Klinik, St. Elisabeth Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • at least 18 years of age, of either sex and any race
  • diagnosis of chronic rhinosinusitis with or without nasal polyposis according to the EPOS guidelines research
  • Subjects should be regularly scheduled for bilateral functional endonasal endoscopic sinus surgery
  • Subjects must be in good health, free of any clinically significant disease that would interfere with the study schedule or procedures or compromise his/her safety.
  • Subjects must be willing to give informed consent and adhere to visit schedules, medication restrictions, and agree to perform daily diary entries.
  • Nonpregnant women of childbearing potential must use a medically acceptable, adequate form of birth control.

Exclusion Criteria:

  • Women must not be pregnant, breast feeding, or premenarcheal.
  • Subjects who have required oral corticosteroids within the previous four weeks prior to surgery.
  • Subjects who have required nasal corticosteroids within the previous one week prior to surgery.
  • Subjects with known allergic reaction on tetracyclines, diabetes (type 1 and 2), renal insufficiency, severe liver disease, systemic diseases affecting the nose (e.g. M. Wegener), prior surgeries of the paranasal sinuses.
  • Patients with the following diseases should be excluded :

    1. Cystic fibrosis based on positive sweat test or DNA alleles
    2. Gross immunodeficiency (congenital or acquired)
    3. congenital mucociliary problems e.g. primary ciliary dyskinesia (PCD)
    4. Non-invasive fungal balls and invasive fungal disease
    5. systemic vasculitis and granulomatous diseases
    6. Cocaine abuse
    7. Neoplasia

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Placebo Comparator: placebo
during 56 days
Experimental: doxycycline 100 mg
during 56 days

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Endoscopic evaluation of quality and speed of wound healing
Time Frame: at 3 months after first drug intake
at 3 months after first drug intake
Recurrence of nasal polyps
Time Frame: at 3 months after first drug intake
at 3 months after first drug intake
Recurrence of nasal polyps
Time Frame: at 6 months after first drug intake
at 6 months after first drug intake

Secondary Outcome Measures

Outcome Measure
Time Frame
nasal and exhaled NO
Time Frame: at 3 months after first drug intake
at 3 months after first drug intake
nasal and exhaled NO
Time Frame: at 6 months after first drug intake
at 6 months after first drug intake
subjective assessment of the wound healing
Time Frame: at 3 months after first drug intake
at 3 months after first drug intake
subjective assessment of the wound healing
Time Frame: at 6 months after first drug intake
at 6 months after first drug intake
chronic rhinosinusitis symptoms by the patients
Time Frame: at 3 months after first drug intake
at 3 months after first drug intake
chronic rhinosinusitis symptoms by the patients
Time Frame: at 6 months after first drug intake
at 6 months after first drug intake
Questionnaires: SNOT 22, RSOM, SF36 asthma control questionnaire
Time Frame: at 3 months after first drug intake
at 3 months after first drug intake
Questionnaires: SNOT 22, RSOM, SF36 asthma control questionnaire
Time Frame: at 6 months after first drug intake
at 6 months after first drug intake
inflammatory mediators in nasal fluid as well as in serum
Time Frame: at 3 months after first drug intake
at 3 months after first drug intake
inflammatory mediators in nasal fluid as well as in serum
Time Frame: at 6 months after first drug intake
at 6 months after first drug intake

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Investigators

  • Principal Investigator: Claus Bachert, MD, PhD, University Hospital Ghent, Belgium

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

November 22, 2011

Primary Completion (Actual)

September 6, 2016

Study Completion (Actual)

February 6, 2017

Study Registration Dates

First Submitted

September 8, 2010

First Submitted That Met QC Criteria

September 9, 2010

First Posted (Estimate)

September 10, 2010

Study Record Updates

Last Update Posted (Actual)

June 15, 2018

Last Update Submitted That Met QC Criteria

June 14, 2018

Last Verified

June 1, 2018

More Information

Terms related to this study

Other Study ID Numbers

  • 2010/384

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.